title: A novel biweekly pancreatic cancer treatment schedule with gemcitabine, 5-fluorouracil and folinic acid.
abstract: Pancreatic adenocarcinoma is a common disease considered to be poorly responsive to antiblastic treatment. Recent clinical and preclinical results suggest that a combined treatment of gemcitabine (GEM), 5-flurouracil (5-FU) and folinic acid (FA) offers a clinical benefit in patients with advanced pancreas adenocarcinoma. The aim of this phase II clinical trial was to evaluate the antitumour activity and toxicity of a novel biweekly schedule of this combination in patients with pancreatic adenocarcinoma. A total of 42 patients received a 30 min infusion of FA (100 mg m(-2)) and 5-FU (400 mg m(-2)) (FUFA) on days 1-3, and GEM 1000 mg m(-2) on day 1 every 15 days. We observed 13 objective responses (two complete, 11 partial) and 23 stable diseases. The median time to progression was 9.75 months (95% Confidence Interval (CI), 6.88-12.62) and the median overall survival was 13.10 months (95% CI 9.64-16.56). There were seven cases of each grade III gastroenteric and haematological toxicity. The GEM plus FUFA combination appears to be well tolerated and very active in patients with pancreatic carcinoma.
authors.affiliation: Oncology Section, Department of Human Pathology and Oncology, Siena University School of Medicine, Viale Bracci 11, 53100 Siena, Italy. francini@unisi.it
authors.forename: P
authors.initials: P
authors.lastname: Correale
authors.forename: S
authors.initials: S
authors.lastname: Messinese
authors.forename: S
authors.initials: S
authors.lastname: Marsili
authors.forename: F
authors.initials: F
authors.lastname: Ceciarini
authors.forename: D
authors.initials: D
authors.lastname: Pozzessere
authors.forename: R
authors.initials: R
authors.lastname: Petrioli
authors.forename: M
authors.initials: M
authors.lastname: Sabatino
authors.forename: D
authors.initials: D
authors.lastname: Cerretani
authors.forename: M
authors.initials: M
authors.lastname: Pellegrini
authors.forename: T
authors.initials: T
authors.lastname: Di Palma
authors.forename: A
authors.initials: A
authors.lastname: Neri
authors.forename: A
authors.initials: A
authors.lastname: Calvanese
authors.forename: E
authors.initials: E
authors.lastname: Pinto
authors.forename: G
authors.initials: G
authors.lastname: Giorgi
authors.forename: G
authors.initials: G
authors.lastname: Francini
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D018450:Disease Progression; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007262:Infusions, Intravenous; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016019:Survival Analysis; D016896:Treatment Outcome; D000093542:Gemcitabine
chemical_list: D003841:Deoxycytidine; D002955:Leucovorin; D005472:Fluorouracil; D000093542:Gemcitabine